Expert Interview
A second look: Discussing the ongoing Karyopharm Therapeutics' SENTRY trial Evaluating Selinexor in Combination with Ruxolitinib in JAKi-Naive Myelofibrosis patients
Ticker(s): KPTI, INCYInstitution: University of Utah
- Professor in the Division of Hematology and Hematologic Malignancies & Huntsman Cancer Institute Investigator at the University of Utah.
- Member of the Cell Response and Regulation Program and the Imaging, Diagnostics, and Therapeutics Program.
- Research focuses on elucidating the molecular basis of hematological diseases to discover their either somatic or germline underlying mutations and then determine the functions of the mutations.
Do yo have any high level thoughts on XPO1 inhibition to treat myelofibrosis?
Added By: wilson_adminDo you have any concerns about potential AEs from selinexor?
Added By: wilson_adminWhat would SENTRY need to show from selinexor to justify using in combination instead of just using a monotherapy JAKi?
Added By: wilson_admin1) How much can TSS be reduced with selinexor beyond ruxolitinib?
2) What delta do you forecast?
Do you believe it's possible the study will hit on both SVR35 and TSS? If it hits SVR but misses TSS, what do you believe are the clinical implications?
Added By: wilson_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
